{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:59:52Z","timestamp":1790276392408,"version":"4.1.0"},"reference-count":48,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MU 3565\/3-0"],"award-info":[{"award-number":["MU 3565\/3-0"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GU 883\/3-0"],"award-info":[{"award-number":["GU 883\/3-0"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 01.702"],"award-info":[{"award-number":["TTU 01.702"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013\u20132016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.<\/jats:p>","DOI":"10.3390\/v12090915","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T09:35:31Z","timestamp":1597916131000},"page":"915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-2808","authenticated-orcid":false,"given":"Till","family":"Koch","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"},{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rottstegge","sequence":"additional","affiliation":[{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-4497","authenticated-orcid":false,"given":"Paula","family":"Ruibal","sequence":"additional","affiliation":[{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Gomez-Medina","sequence":"additional","affiliation":[{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily V.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3655-0525","authenticated-orcid":false,"given":"Beatriz","family":"Escudero-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pillny","sequence":"additional","affiliation":[{"name":"Clinical Psychology and Psychotherapy, Institute of Psychology, Faculty of Psychology and Human Movement Science, University of Hamburg, 20146 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My Linh","family":"Ly","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"},{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara Raymond","family":"Koundouno","sequence":"additional","affiliation":[{"name":"Ministry of Health Guinea, 2101 Conakry, Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Akoi","family":"Bore","sequence":"additional","affiliation":[{"name":"Ministry of Health Guinea, 2101 Conakry, Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u2019Faly","family":"Magassouba","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Gamal Abdel Nasser de Conakry, 2101 Conakry, Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dahlke","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"},{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Research and Development Institute, National Infection Service, Public Health England, Porton Down, Salisbury, Wilts SP40JG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-9224","authenticated-orcid":false,"given":"Marylyn M.","family":"Addo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"},{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-2586","authenticated-orcid":false,"given":"C\u00e9sar","family":"Mu\u00f1oz-Fontela","sequence":"additional","affiliation":[{"name":"Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infection Research, partner site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1473-3099(20)30185-7","article-title":"Ebola virus disease in DR Congo","volume":"20","author":"Burki","year":"2020","journal-title":"Lancet Infect. Dis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature17949","article-title":"Unique human immune signature of Ebola virus disease in Guinea","volume":"533","author":"Ruibal","year":"2016","journal-title":"Nature"},{"key":"ref_4","first-page":"287","article-title":"Comprehensive characterization of cellular immune responses following Ebola virus infection","volume":"215","author":"Dahlke","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_5","first-page":"S796","article-title":"Ebola Virus Disease in Humans: Pathophysiology and Immunity","volume":"204","author":"McElroy","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chom.2020.01.001","article-title":"Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design","volume":"27","author":"Khurana","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Colavita, F., Biava, M., Castilletti, C., Lanini, S., Miccio, R., Portella, G., Vairo, F., Ippolito, G., Capobianchi, M.R., and Di Caro, A. (2019). Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014\u20132016 Outbreak in West Africa. Viruses, 11.","DOI":"10.3390\/v11040373"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chom.2017.07.013","article-title":"Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design","volume":"22","author":"Crowe","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: Antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/infdis\/jix584","article-title":"Ebola Virus Neutralizing Antibodies Detectable in Survivors of the Yambuku, Zaire Outbreak 40 Years after Infection","volume":"217","author":"Rimoin","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1038\/s41598-017-06226-8","article-title":"Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind Fc\u03b3RI","volume":"7","author":"Radinsky","year":"2017","journal-title":"Sci Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Oswald, W.B., Geisbert, T.W., Davis, K.J., Geisbert, J.B., Sullivan, N.J., Jahrling, P.B., Parren, P.W.H.I., and Burton, D.R. (2007). Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog, 3.","DOI":"10.1371\/journal.ppat.0030009"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chom.2018.12.004","article-title":"Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection","volume":"25","author":"Wec","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virusres.2015.12.019","article-title":"Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus","volume":"213","author":"Luczkowiak","year":"2016","journal-title":"Virus Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1128\/JVI.01439-18","article-title":"Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection","volume":"93","author":"Williamson","year":"2019","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_19","unstructured":"Administration, F.A.D. (2020, August 18). First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response. Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.chom.2020.01.007","article-title":"Structural Basis for a Convergent Immune Response against Ebola Virus","volume":"27","author":"Zehner","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat. Med."},{"key":"ref_23","first-page":"8","article-title":"Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination","volume":"27","author":"Wagstaffe","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"228ra38","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","author":"Chung","year":"2014","journal-title":"Sci. Transl Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/JVI.00198-11","article-title":"CAPRISA002 Study Team The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection","volume":"85","author":"Gray","year":"2011","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00430-011-0200-7","article-title":"Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer","volume":"201","author":"Pastrana","year":"2012","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1172\/JCI83111","article-title":"Blood kinetics of Ebola virus in survivors and nonsurvivors","volume":"125","author":"Lanini","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"(2015). Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J. Clin. Investig., 125, 4421\u20134428.","DOI":"10.1172\/JCI83162"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1212\/WNL.42.4.761","article-title":"Severe tetanus in immunized patients with high anti-tetanus titers","volume":"42","author":"Crone","year":"1992","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1574-6968.1991.tb04211.x","article-title":"Neonatal tetanus despite protective serum antitoxin concentration","volume":"3","author":"Maselle","year":"1991","journal-title":"FEMS Microbiol. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"158ra146","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.smim.2018.07.003","article-title":"Correlates of vaccine-induced protective immunity against Ebola virus disease","volume":"39","author":"Medaglini","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","article-title":"Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?","volume":"27","author":"Meyer","year":"2019","journal-title":"Trends Microbiol."},{"key":"ref_37","unstructured":"(2016). Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection. Nat. Commun., 7, 11826."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4049\/jimmunol.1100783","article-title":"Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells","volume":"188","author":"Foote","year":"2012","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4049\/jimmunol.1002836","article-title":"IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection","volume":"186","author":"Racine","year":"2011","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/infdis\/jiu088","article-title":"Ebola hemorrhagic fever: Novel biomarker correlates of clinical outcome","volume":"210","author":"McElroy","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"(2014). Case of Severe Ebola Virus Infection Complicated by Gram-Negative Septicemia. N. Engl. J. Med., 371, 2394\u20132401.","DOI":"10.1056\/NEJMoa1411677"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1128\/JVI.01033-16","article-title":"Ferrets infected with Bundibugyo virus or Ebola virus recapitulate important aspects of human filoviral disease","volume":"90","author":"Kozak","year":"2016","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAI.0b013e3182100c1b","article-title":"Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity","volume":"57","author":"Sajadi","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nicholas, K.J., Zern, E.K., Barnett, L., Smith, R.M., Lorey, S.L., Copeland, C.A., Sadagopal, S., and Kalams, S.A. (2013). B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084185"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20140245","DOI":"10.1098\/rstb.2014.0245","article-title":"Trade-offs in antibody repertoires to complex antigens","volume":"370","author":"Childs","year":"2015","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses","volume":"221","author":"Gunn","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41591-019-0607-z","article-title":"A glimpse into immune responses evolving against Ebola virus","volume":"25","author":"Saphire","year":"2019","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"20054","DOI":"10.1073\/pnas.1911842116","article-title":"Differential requirements for Fc\u03b3R engagement by protective antibodies against Ebola virus","volume":"116","author":"Bournazos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/9\/915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:04:15Z","timestamp":1760177055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/9\/915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["v12090915"],"URL":"https:\/\/doi.org\/10.3390\/v12090915","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}